A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

Speciality: Oncology


Speaker:

Dr. Jessicca Lin | Attending Physician, Center for Thoracic Cancers & Henri and Belinda Termeer center for Targeted Therapies

Dr. T. Raja | Director of Medical Oncology, Senior Consultant in BMT Apollo Hospital

Dr. Amit Rauthan | Consultant in Medical Oncology, Hemato-Oncology & Transplant Manipal Hospital

Dr. B. K. Smruti | Consultant Medical Oncologist, Hemato-Oncologist, Bombay Hospital Institute of Medical Science

Description:

A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.

In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.

Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.

ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.

Therefore,  you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Childhood cancer survivors face new health problems later in life, study shows

2.

FDA Approves Subcutaneous Isatuximab for MM Indications

3.

Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer

4.

Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.

5.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot